Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability. FXS affects both men and women and the condition is also linked to other neurological and psychiatric disorders (CDC, 2017a). FXS is caused by an abnormal expansion in the number of the trinucleotide CGG repeats located in the 5' UTR in the fragile X mental retardation 1 gene (FMR1) at Xq27.3. Patients affected with FXS have more than 200 repeats of the CGG trinucleotide caused by the full mutation of FMR1 gene (NFXF, 2017; Saldarriaga et al., 2014).
In the 7MM, the diagnosed prevalent cases of FXS are expected to increase from around 88,000 cases in 2016 to over 91,000 cases in 2026, at an Annual Growth Rate (AGR) of about 0.39% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed prevalent cases of FXS will increase from about 36,900 cases in 2016 to over 37,000 cases in 2026, at an AGR of about 0.2%. When examining the AGR by individual markets, forecasts that all markets will see an increase in the diagnosed prevalent cases of FXS during the forecast period except Germany and Japan, with AGRs of negative 0.22% and negative 0.31% respectively, during the forecast period.
The report "EpiCast Report: Fragile X Syndrome - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for FXS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed prevalent cases of FXS segmented by age (0-19 years, 20-39 years, 40-59 years, 60-79 years, and 80 years and older) and sex in these markets.
- The Fragile X Syndrome (FXS) EpiCast Report provides an overview of the risk factors and global trends of FXS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of FXS in these markets from 2016-2026. The prevalent cases are further segmented by age (0-19 years, 20-39 years, 40-59 years, 60-79 years, and 80 years and older) and sex.
- The FXS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The FXS EpiCast report will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global FXS market.
- Quantify patient populations in the global FXS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for FXS therapeutics in each of the markets covered.
2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for FXS (2016-2026)
3.5.1 Diagnosed Prevalent Cases of FXS
3.5.2 Age-Specific Diagnosed Prevalent Cases of FXS
3.5.3 Sex-Specific Diagnosed Prevalent Cases of FXS
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
List of Tables
Table 1: Comorbidities for FXS
Table 2: 7MM, Diagnosed Prevalent Cases of FXS, All Ages, Both Sexes, N, 2016-2026
List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of FXS, Both Sexes, All Ages, N, 2016 and 2026
Figure 2: 7MM, Sources Used, Diagnosed Prevalent Cases of FXS
Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of FXS, Both Sexes, N, 2016
Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of FXS, All Ages, N, 2016